India’s Enzene Biosciences to Open a $50M Bio-Manufacturing Plant in Hopewell

The new 55,000-square-foot facility will bring 300 jobs to the state

On Jun 15, 2023

Enzene Biosciences, Ltd., a global biotech company based in Pune, India, will open a state-of-the-art biopharmaceutical manufacturing plant on the Princeton West Innovation Campus in Hopewell. Operations in the new facility, the company’s first location outside of India, are expected to begin in June 2024. As part of Enzene’s expansion plans, the company will initially hire 50 employees and grow to 300 employees at its New Jersey facility.

As a contract development and manufacturing organization (CDMO), Enzene Biosciences, a subsidiary of Alkem Laboratories, Ltd., provides services to global pharmaceutical companies, partnering with them in their drug development and manufacturing processes.

“The strong relationship between New Jersey and India has gained increasing momentum since we opened the New Jersey India Center to cultivate economic opportunities during our trip to the country in 2019,” said Gov. Phil Murphy. “I am proud to welcome Enzene Biosciences and its expanding global presence to New Jersey’s flourishing life sciences industry. [The company’s] state-of-the-art manufacturing facility will bring hundreds of jobs and generate $50 million in economic investments in our state, further solidifying New Jersey’s position as an innovation economy leader.”

“We are proud to welcome Enzene to New Jersey’s thriving life sciences ecosystem,” said Wesley Mathews, president and CEO of Choose New Jersey. “Yet another Indian biopharma company has established itself in the state, demonstrating the strength of the New Jersey-India economic partnership. Beyond economic and commercial ties, our academic and cultural connections make it the perfect fit for Indian companies looking to expand to North America. Enzene’s growth in this sector highlights New Jersey’s global presence throughout all areas of the biopharmaceutical industry — from clinical trials to large-scale manufacturing.”

“[We are] thrilled to establish our manufacturing operations in New Jersey, as it allows us to extend our local manufacturing capabilities to our valued North American clients,” said Dr. Himanshu Gadgil, CEO of Enzene Biosciences. “We are excited to provide them with access to our cutting-edge continuous manufacturing platform, which enables streamlined and efficient production processes. New Jersey’s highly skilled workforce, state-of-the-art infrastructure, and renowned academic institutions make it an ideal location for Enzene, ensuring that we can deliver exceptional services and support to our clients in the U.S.”

Choose New Jersey met representatives from Enzene during a business attraction mission to India in 2022. With assistance from Choose New Jersey, Enzene connected with in-state partners, including construction firms, human resources and payroll services, business insurance providers, township leadership, and universities. Reed Smith facilitated Enzene’s legal needs, and JLL Capital Markets represented the property.

“We are thrilled that Enzene Biosciences has chosen Princeton as the location for its new biomanufacturing facility – Enzene’s only U.S. site,” said Debbie Hart, BioNJ president and CEO. “With its extensive drug development know-how and experience, Enzene will be a valuable addition to New Jersey’s robust life sciences ecosystem – bringing innovative medicines to Patients around the world. A leading biomedical hub, the Garden State boasts a full complement of large and small biopharmaceutical companies, universities, research institutions, clinical research organizations, and service providers working together to make meaningful advances in healthcare.”

Enzene’s local manufacturing capabilities will provide North American biopharmaceutical companies with streamlined supply chains, fast turnaround times, enhanced communication, and greater control over the manufacturing process. By providing comprehensive manufacturing capabilities under one roof, Enzene is well-positioned to support the development and production of a diverse range of biologics, contributing to the advancement of global healthcare and positively impacting patients’ lives worldwide.

To access more business news, visit NJB News Now.

Related Articles: